scholarly journals A procedure to detect 6 basic STSs and 11 extended STSs in the AZF region using multiplex PCR

2021 ◽  
Vol 63 (3) ◽  
pp. 48-55
Author(s):  
Thi Lan Anh Luong ◽  
◽  
Thu Lan Hoang ◽  
Minh Ngoc Nguyen ◽  
Ngoc Dung Nguyen ◽  
...  

Microdeletions of Y chromosomes frequently occur in 3 subregions of the AZF, namely, AZFa, AZFb, and AZFc, with 6 basic STS marker sequences, which are sY84, sY86 (AZFa), sY127, sY134 (AZFb), and sY254, sY255 (AZFc). According to EAA/EMNQ guidelines, 11 additional AZFabc marker sequences should be used to determine the extent of the microdeletion in the AZF region of infertile men, which is known as 11 extended STSs. By applying mPCR, the authors develop an optimal detection procedure for the 6 basic STS and 11 extended STS using 3 multiplex PCR reactions. The first multiplex PCR reaction includes 6 basic STS plus the 2 control sequences sex-determining region Y (SRY) and zinc finger protein X/Y-linked (ZFX/Y). The second multiplex PCR reaction includes the 6 extended STS sY88, sY1182, sY105, sY121, sY1191, and sY1291 and the 2 control sequences SRY and ZFX/Y. The third multiplex PCR reaction includes the 5 extended STS sY153, sY160, sY82, sY143, and sY83 and the 2 control sequences SRY and ZFX/Y. Six basic primer sequences and eleven extended primer sequences are redesigned to simultaneously pair and amplify STS in the same multiplex reaction: set of 8 primers for 6 basic STS: 6 basic STS + 2 (SRY, ZFX/Y), 8 extension primers set E1: 6 extended STS + 2 (SRY, ZFX/Y), and 7 extension primers set E2: 5 extended STS + 2 (SRY, ZFX/Y). We successfully designed primer pairs with high specificity and stability and successfully amplified 6 basic STS and 11 extended STS, which ensures that the STSs have the correct sequence as recommended by EAA/EMQN and are consistent with the NCBI gene bank. This study has successfully developed a procedure to simultaneously detect 17 STSs, including 6 basic STSs and 11 extended STSs in the AZF region using 3 multiplex PCR reactions.

2021 ◽  
Author(s):  
Gideon Carney ◽  
Duncan Bush ◽  
Scarlet Sellers ◽  
Roan Carpenter ◽  
Maira Hewitt ◽  
...  

Abstract We analyzed published tumor transcriptome data in conjunction with linked survival data to identify genes linked with breast cancer survival outcomes (1, 2). When comparing tumor transcriptomes based on 24-month survival, we discovered that the zinc-finger protein X-linked ZFX (3, 4) was among the most differentially expressed genes in both original and metastatic tumor tissues. ZFX expression was considerably enhanced in metastatic tumors of patients who survived more than 24 months, indicating that enhanced ZFX expression offers a survival advantage for patients with stage IV metastatic breast cancer.


2017 ◽  
Vol 11 (5) ◽  
pp. 455-469 ◽  
Author(s):  
Chao Wang ◽  
Si-yuan Fu ◽  
Ming-da Wang ◽  
Wen-bo Yu ◽  
Qin-shu Cui ◽  
...  

2020 ◽  
Author(s):  
Shahan Mamoor

We mined published tumor transcriptome data with paired survival data to discover genes associated with survival outcomes in breast cancer (1, 2). We found that the zinc-finger protein X-linked ZFX (3, 4) was among the genes most differentially expressed in both primary and metastatic tumor tissues when comparing tumor transcriptomes based on survival at 24 months. ZFX expression was significantly higher in the metastatic tumors of patients surviving greater than 24 months, suggesting that increased ZFX expression confers a survival benefit to patients with stage IV metastatic breast cancer.


Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 4247-4247
Author(s):  
Xiuyan Zhang ◽  
Yu Wang ◽  
Lun Xiao ◽  
Haixia Zhou ◽  
Li Zhu ◽  
...  

Abstract Zinc Finger protein, X-linked (ZFX) is a transcriptional regulator, which controls the self-renewal of both embryonic and hematopoietic stem cells and participates in pathogenesis of various cancers. Zfx deficiency impairs Notch intracellular domain (NotchIC) induced acute T-cell leukemia (T-ALL) or MLL-AF9 induced acute myeloid leukemia (AML) in mice models. However, the function of ZFX in chronic myeloid leukemia (CML) stem/progenitor cells has not been elucidated yet. In the present study, qRT-PCR analysis showed that ZFX expression was significantly higher in CD34+ cells from CML patients in chronic phase (CP) (n=8, 3.1-fold, P=0.0052) and patients in blast crisis (BC) (n=8, 18.6-fold, P=0.0050) compared with that in healthy donors (n=4). Two independent shRNA sequences against ZFX were delivered in CD34+ cells with lentiviral vector. The silence of ZFX had a stronger inhibitory effect on colony-forming cell (CFC) ability of CML CD34+ cells (75±5%) than that of healthy donor CD34+ cells (44±5%). Furthermore, ZFX silencing augmented Imatinib Mesylate (IM) sensitivity of CML CD34+ cells, especially in IM-resistant samples; due to the fact that ZFX silencing increased apoptosis induced by IM. To obtain the molecular insights of how ZFX acts, we generated transcriptome data comparing ZFX silenced CML CD34+ cells with control cells. qRT-PCR data validated that ZFX silencing caused a significantly declined expression of WNT3 in K562, MEG-01 and CML CD34+ cells (n=5). In addition, ZFX silencing decreased WNT3 protein expression as well. Interestingly, WNT3 had significantly higher expression in CD34+ cells from patients in CP (n=10, 5-fold, P=0.0006) compared with that in healthy donors (n=8). Silence of WNT3 inhibited the growth of K562 cells and enhanced IM sensitivity of these cells as well. Overexpression of WNT3 restored the growth inhibition and IM hypersensitivity upon ZFX silencing. Chromatin immunoprecipitation (ChIP) analysis revealed that ZFX was able to bind with WNT3 promoter, and luciferase assay showed that ZFX silencing significantly decreased the activity of WNT3 promoter. Finally, we also found that the expressions of c-Myc and cyclin D1 were reduced by ZFX silencing or WNT3 silencing, suggesting decreased WNT/Catenin signaling. Taken together, we have demonstrated that ZFX is aberrantly expressed in CML stem/progenitor cells, and it modulates the growth and IM response of CML stem/progenitor cells via wnt/Catenin pathway indicating ZFX is a new regulator of CML stem/progenitor cells, which deepens the understanding of CML pathology and potentially provides clues for novel therapies against this disease. Disclosures No relevant conflicts of interest to declare.


Tumor Biology ◽  
2015 ◽  
Vol 36 (8) ◽  
pp. 6103-6112 ◽  
Author(s):  
Hongzhi Ma ◽  
Fan Yang ◽  
Meng Lian ◽  
Ru Wang ◽  
Haizhou Wang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document